Understanding the benefits of GLP-1 drugs beyond obesity
In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including…
Two plant extracts with potential as GLP-1 agonist weight loss pills are identified by AI-based analysis
Two plant compounds with potential as GLP-1 agonist weight loss pills have been identified in an AI (artificial intelligence)-based study, the European Congress on Obesity (ECO 2024) (Venice 12-15 May),…